Given a hereditary origin of progressive hearing loss through KCNQ4 dysfunction, as it occurs in DFNA2 non-syndromic autosomal-dominant progressive high-frequency hearing loss [155, 157], genetic therapeutic approaches have been envisioned, e.g., those following heterologic expression of wild-type channels that could be combined with KV7 channel openers such as retigabine [181]. Here, KCNQ4 is linked to hearing loss disorder.